• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>The Journal of Clinical Pharmacology: Official Journal of the American College of Clinical Pharmacology >Clinical manifestation of atherosclerotic peripheral arterial disease and the role of cilostazol in treatment of intermittent claudication.
【24h】

Clinical manifestation of atherosclerotic peripheral arterial disease and the role of cilostazol in treatment of intermittent claudication.

机译：动脉粥样硬化性外周动脉疾病的临床表现以及西洛他唑在治疗间歇性lau行中的作用。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Intermittent claudication (IC) is the symptomatic expression of peripheral arterial disease (PAD), which itself is a manifestation of systemic atherosclerosis. Like other forms of atherosclerosis, PAD is associated with elevated rates of cardiovascular and cerebrovascular morbidity and mortality. Until recently, therapeutic options for the treatment of the symptoms of IC have been limited, and the efficacy of available treatment has been questioned. Cilostazol, a selective phosphodiesterase III inhibitor with vasodilator, antiplatelet, and antiproliferative properties, has recently been approved for the treatment of IC symptoms in the United States. Cilostazol significantly improves maximal and pain-free walking distances. Clinical studies have also demonstrated that cilostazol favorably alters plasma lipids (elevates HDL-cholesterol, lowers triglycerides). These properties may contribute to the benefit of this drug in IC and in other diseases secondary to atherosclerosis.
机译：间歇性lau行（IC）是外周动脉疾病（PAD）的症状表现，其本身是系统性动脉粥样硬化的表现。像其他形式的动脉粥样硬化一样，PAD与心血管和脑血管发病率和死亡率的上升有关。直到最近，用于治疗IC症状的治疗选择一直受到限制，并且对可用治疗的有效性提出了质疑。西洛他唑是一种具有血管扩张剂，抗血小板和抗增殖特性的选择性磷酸二酯酶III抑制剂，最近在美国被批准用于治疗IC症状。西洛他唑显着改善了最大且无痛苦的步行距离。临床研究还表明，西洛他唑有利地改变血浆脂质（升高HDL-胆固醇，降低甘油三酸酯）。这些特性可能有助于该药物在IC和其他继发于动脉粥样硬化的疾病中的获益。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号